The principles of agonist pharmacotherapy for psychostimulant dependence

References

• White F, Kalivas P. Neuroadaptions involved in amphetamine and cocaine addiction. Drug Alcohol Depend 1998; 51: 141–153
   PubMed Web of Science ®Google Scholar
• Rawson R, Huber A, Brethen P, et al. Methamphetamine and cocaine users: differences in characteristics and treatment retention. J Psychoact Drugs 2000; 21: 233–238
   Google Scholar
• Copeland A, Sorenson J. Differences between methamphetamine users and cocaine users in treatment. Drug Alcohol Depend 2001; 62: 91–95
   PubMed Web of Science ®Google Scholar
• Wise R. Neurobiology of addiction. Curr Opin Neurobiol 1996; 6: 243–251
   PubMed Web of Science ®Google Scholar
• Kuhar M J, Ritz M C, Boja J W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991; 14: 299–302
   PubMed Web of Science ®Google Scholar
• Koob G. Neurobiology of addiction: toward the development of new therapies. Ann NY Acad Sci 2000; 909: 170–185
   PubMed Web of Science ®Google Scholar
• Volkow N, Fowler J, Wang G-J, Swanson J. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004; 9: 557–569
   PubMed Web of Science ®Google Scholar
• Bardo M. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit Rev Neurobiol 1998; 12: 37–67
   PubMed Web of Science ®Google Scholar
• Gold M, Miller M. Cocaine (and crack): neurobiology. Substance abuse: a comprehensive textbook, chapter 15, J Lowinson, P Ruiz, R Millman, J Langrod. Williams & Wilkins, Baltimore 1997:166 – 81
   Google Scholar
• Dackis C, Gold M. New concepts in cocaine addiction: the dopamine depletion theory. Neurosci Biobehav Rev 1985; 9: 469–477
   PubMed Web of Science ®Google Scholar
• Dackis C, O'Brien C. Cocaine dependence: a disease of the brain's reward centers. J Subst Abuse Treat 2001; 12: 111–117
   Google Scholar
• Spanagel R, Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci 1999; 22: 521–527
   PubMed Web of Science ®Google Scholar
• Kuhar M, Pilotte N. Neurochemical changes in cocaine withdrawal. Trends Pharmacol Sci 1996; 17: 260–264
   PubMed Web of Science ®Google Scholar
• Nader M A, Morgan D, Gage H D, et al. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat Neurosci 2006; 9: 1050–1056
   PubMed Web of Science ®Google Scholar
• Volkow N D, Wang G J, Fowler J S, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997; 386: 830–833
   PubMed Web of Science ®Google Scholar
• Volkow N D, Chang L, Wang G-J, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158: 377–382
   PubMed Web of Science ®Google Scholar
• Ross E. Pharmacodynamics. Goodman & Gilman's The pharmacological basis of therapeutics, chapter 2, 9th edn, L Goodman, A Gilman. McGraw-Hill, New York 1996:29 – 41
   Google Scholar
• Neal M. Medical pharmacology at a glance, 4th edn. Blackwell Science, Oxford 2002
   Google Scholar
• Dole V P, Robinson J W, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med 1969; 280: 1372–1375
   PubMed Web of Science ®Google Scholar
• Newman R G, Whitehill W B. Double-blind comparison of methadone and placebo maintenance treatments of narcotics addicts in Hong Kong. Lancet 1979; 2: 485–488
   PubMed Web of Science ®Google Scholar
• Gunne L-M, Grönbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend 1981; 7: 249–256
   PubMed Web of Science ®Google Scholar
• Sees K L, Delucchi K L, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000; 283: 1303–1310
   PubMed Web of Science ®Google Scholar
• Gearing F R, Schweitzer M D. An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction. Am J Epidemiol 1974; 100: 101–112
   PubMed Web of Science ®Google Scholar
• Caplehorn J RM, Dalton M SYM, Cluff M C, Petrenas A M. Retention in methadone maintenance and heroin addicts' risk of death. Addiction 1994; 89: 203–207
   PubMed Web of Science ®Google Scholar
• Langendam M W, van Brussel G HA, Coutinho R A, van Ameijden E JC. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health 2001; 91: 774–780
   PubMed Web of Science ®Google Scholar
• Julien R. A primer of drug action. Henry Holt and Company, New York 2001
   Google Scholar
• Mattick R, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo versus methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2004;3:CD002207
   PubMedGoogle Scholar
• Kirchmayer U, Davoli M, Verster A, Amato L, Ferri M, Perucci C A. A systematic review on the efficacy of naltrexone maintenance treatment in opioid treatment. Addiction 2002; 97: 1241–1249
   PubMed Web of Science ®Google Scholar
• Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2002;4:CD000146
   PubMedGoogle Scholar
• Tonnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation, European Respiratory Society. Eur Respir J 1999 1999; 13: 238–246
   Google Scholar
• Gonzales D, Rennard S I, Nides M, et al. Varenicline, an {alpha}4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47–55
   PubMed Web of Science ®Google Scholar
• Jorenby D E, Hays J T, Rigotti N A, et al. Efficacy of varenicline, an {alpha}4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56–63
   PubMed Web of Science ®Google Scholar
• Soares B, Lima M, Reisser A, Farrell M. Dopamine agonists for cocaine dependence [Cochrane Review]. John Wiley & Sons, Ltd, Chichester 2006, The Cochrane Library, Issue 4, 2006
   Google Scholar
• Sevarino K, Oliveto A, Kosten T. Neurobiological adaptions to psychostimulants and opiates as a basis of treatment development. Ann NY Acad Sci 2000; 909: 51–87
   PubMed Web of Science ®Google Scholar
• Malcolm R, Moore J, Kajdasz D, Cochrane C. Adverse events occurring in the treatment of cocaine dependence. Am J Addict 1997; 6: 117–123
   PubMed Web of Science ®Google Scholar
• Dackis C, O'Brien C. Cocaine dependence: the challenge for pharmacotherapy. Curr Opin Psychiatry 2002; 15: 261–267
   Web of Science ®Google Scholar
• Kampman K, Volpicelli J, Alterman A, Cornish J, O'Brien C. Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms. Am J Psychiatry 2000; 157: 2052–2054
   PubMed Web of Science ®Google Scholar
• Kampman K, Dackis C, Lynch K, et al. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug Alcohol Depend 2006; 85: 129–137
   PubMed Web of Science ®Google Scholar
• Shearer J, Gowing L. Pharmacotherapies for problematic psychostimulant use: a review of current research. Drug Alcohol Rev 2004; 23: 203–211
   PubMed Web of Science ®Google Scholar
• Nann-Vernotica E, Donny E, Bigelow G, Walsh S. Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. Psychopharmacologia 2001; 155: 38–47
   Web of Science ®Google Scholar
• Haney M, Ward A, Foltin R, Fischman M. Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacologia 2001; 155: 330–337
   PubMed Web of Science ®Google Scholar
• McCance-Katz E, Kosten T, Kosten T. Going from the bedside back to the bench with ecopipam: a new strategy for cocaine pharmacotherapy development. Psychopharmacology 2001; 155: 327–329
   PubMed Web of Science ®Google Scholar
• Evans S, Walsh S, Levin F, Foltin R, Fischman M, Bigelow G. Effect of flupenthixol on subjective and cardiovascular responses to intravenous cocaine in humans. Drug Alcohol Depend 2001; 64: 271–283
   PubMed Web of Science ®Google Scholar
• Grabowski J, Rhoades H, Silverman P. Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. J Clin Psychopharmacol 2000; 20: 305–310
   PubMed Web of Science ®Google Scholar
• Kampman K, Pettinati H, Lynch K, Sparkman T, O'Brien C. A pilot study of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend 2003; 70: 265–273
   PubMed Web of Science ®Google Scholar
• Fleming P. Prescribing amphetamine to amphetamine users as a harm reduction measure. Int J Drug Policy 1998; 9: 339–344
   Google Scholar
• Shearer J, Sherman J, Wodak A, van Beek I. Substitution therapy for amphetamine users. Drug Alcohol Rev 2002; 21: 179–185
   PubMed Web of Science ®Google Scholar
• Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004; 29: 969–981
   PubMed Web of Science ®Google Scholar
• Lile J. Pharamcological determinants of the reinforcing effects of psychostimulants: relation to agonist substitution treatment. Exp Clin Psychopharmacol 2006; 14: 20–33
   PubMed Web of Science ®Google Scholar
• Volkow N D, Wang G J, Fowler J S. Imaging studies of cocaine in the human brain and studies of the cocaine addict. Ann NY Acad Sci 1997; 820: 1325–1331
   Web of Science ®Google Scholar
• Shearer J. Psychosocial approaches to psychostimulant dependence: a systematic review. J Subst Abuse Treat 2007; 32: 41–52
   PubMed Web of Science ®Google Scholar
• Baker A, Lee N. A review of psychosocial interventions for amphetamine use. Drug Alcohol Rev 2003; 22: 323–335
   PubMed Web of Science ®Google Scholar
• Shearer J, Wodak A, Mattick R, et al. Pilot randomised controlled study of dexamphetamine for amphetamine dependence. Addiction 2001; 96: 1289–1296
   PubMed Web of Science ®Google Scholar
• Shearer J, Wodak A, van Beek I, Mattick R, Lewis J. Pilot randomised double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 2003; 98: 1137–1141
   PubMed Web of Science ®Google Scholar
• Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocaine-dependence treatment: a double blind randomised clinical trial. J Clin Psychopharmacol 2001; 21: 522–526
   PubMed Web of Science ®Google Scholar
• McBride A, Sullivan G, Blewett A, Morgan S. Amphetamine prescribing as a harm reduction measure: a preliminary study. Addict Res 1997; 5: 95–112
   Web of Science ®Google Scholar
• Charnaud B, Griffiths V. Levels of intravenous drug misuse among clients prescribed oral dexamphetamine or oral methadone: a comparison. Drug Alcohol Depend 1998; 52: 79–84
   PubMed Web of Science ®Google Scholar
• Klee H, Wright S, Carnwath T, Merrill J. The role of substitute therapy in the treatment of problem amphetamine use. Drug Alcohol Rev 2001; 20: 417–429
   Web of Science ®Google Scholar
• Merrill J, McBride A, Pates R, et al. Dexamphetamine substitution as a treatment of amphetamine dependence: a two-centre randomised controlled trial. UK Department of Health, London 2004, Final report submitted to the Department of Health
   Google Scholar
• Grabowski J, Roache J, Schmitz J, Rhoades H, Creson D, Korzun A. Replacement medication for cocaine dependence. Exp Clin Psychopharmacol 1997; 17: 247–249
   Google Scholar
• Schubiner H, Saules K, Arfken C, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002; 10: 286–294
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Kuoppasalmi K, Foehr J, et al. A comparison of aripiprazole, methylphenidate and placebo for amphetamine dependence. Am J Psychiatry 2007; 164: 160–162
   PubMed Web of Science ®Google Scholar
• Fleming P, Roberts D. Is the prescription of amphetamine justified as a harm reduction measure?. J Roy Soc Health 1994; 114: 127–131
   PubMedGoogle Scholar
• Sherman J. Dexamphetamine for ‘speed’ addiction. Med J Aust 1990; 153: 306
   PubMed Web of Science ®Google Scholar
• White R. Dexamphetamine substitution in the treatment of amphetamine abuse: an initial investigation. Addiction 2000; 95: 229–238
   PubMed Web of Science ®Google Scholar
• Carnwath T, Garvey T, Holland M. The prescription of dexamphetamine to patients with schizophrenia and amphetamine dependence. J Psychopharmacol 2002; 16: 373–377
   PubMed Web of Science ®Google Scholar
• White R, Thompson M, Windsor D, Walsh M, Cox D, Charnaud B. Dexamphetamine substitute prescribing in pregnancy: a 10-year retrospective audit. J Subst Use 2006; 11: 205–216
   Google Scholar
• Spear J, Alderton D. Psychosis associated with prescribed dexamphetamine use [letter]. Aust NZ J Psychiatry 2003; 37: 383
   PubMed Web of Science ®Google Scholar
• Hawks D, Mitcheson M, Ogborne A, Edwards G. Abuse of methylamphetamine. BMJ 1969; 85: 715–721
   Google Scholar
• Kall K. Amphetamine abuse in Sweden. Amphetamine misuse, H Klee. Harwood Academic Publishers, Amsterdam 1997; 215–233
   Google Scholar
• Merrill J, McBride A, Pates R. Messages and findings from the Department of Health drugs misuse research initiative: final overview report. Drugs Educ Prev Policy 2005; 12: 94–97
   Web of Science ®Google Scholar
• White J, Wickes W, Longo M. Randomised controlled trial of d-amphetamine maintenance for treatment of methamphetamine dependence. Paper presented at the Australasian Professional Society in Alcohol and Other Drugs (APSAD), Cairns, Queensland, 2006
   Google Scholar
• Gawin F, Riordan C, Kleber H. Methylphenidate treatment of cocaine abusers without attention deficit disorder: a negative report. Am J Drug Alcohol Abuse 1985; 11: 193–197
   PubMed Web of Science ®Google Scholar
• Khantzian E, Gawin F, Riordan C, Kleber H. Methylphenidate treatment of cocaine dependence: a preliminary report. J Subst Abuse Treat 1984; 1: 107–112
   PubMedGoogle Scholar
• Levin F, Evans S, McDowell D, Kleber H. Methylphenidate treatment for cocaine abusers with attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry 1998; 59: 300–305
   PubMed Web of Science ®Google Scholar
• Somoza E, Winhusen T, Bridge T, et al. An open-label pilot study of methylphendaite in the treatment of cocaine dependent patients with adult attention deficit/hyperactivity disorder. J Act Dis 2004; 23: 77–92
   Google Scholar
• Margolin A, Kosten T R, Avants S K, et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend 1995; 40: 125–131
   PubMed Web of Science ®Google Scholar
• Poling J, Oliveto A, Petry N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006; 63: 219–228
   PubMed Web of Science ®Google Scholar
• Newton T, Roache J, de la Garza R, et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006; 31: 1537–1544
   PubMed Web of Science ®Google Scholar
• Mooney M, Schmitz J, Moeller F, Grabowski J. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials. Drug Alcohol Depend 2007; 88: 214–223
   PubMed Web of Science ®Google Scholar
• Cousins M, Roberts D, de Wit H. GABAb receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend 2002; 65: 209–220
   PubMed Web of Science ®Google Scholar
• Kalivas P. Glutamate systems in cocaine addiction. Curr Opin Pharmacol 2004; 4: 23–29
   PubMed Web of Science ®Google Scholar
• Lacey M. Neurotransmitter receptors and ionic conductances regulating the activity of neurones in substantia nigra pars compacta and ventral tegmental area. Prog Brain Res 1993; 99: 251–276
   PubMed Web of Science ®Google Scholar
• Wood P. Actions of the GABAergic agents on dopamine metabolism in the nigrostriatal pathway of the rat. J Pharmacol Exp Ther 1982; 222: 674–679
   PubMed Web of Science ®Google Scholar
• Pycock C, Horton R. Evidence for an accumbens – pallidal pathway in the rat and its possible gabaminergic control. Brain Res 1976; 110: 629–634
   PubMed Web of Science ®Google Scholar
• Tzschentke T, Schmidt W. Glutamatergic mechanisms in addiction. Mol Psychiatry 2003; 8: 373–382
   PubMed Web of Science ®Google Scholar
• Kalivas P, McFarland K, Bowers S, Szumlinski K, Xi Z, Baker D. Glutamate transmission and addiction to cocaine. Ann NY Acad Sci 2003; 1003: 169–175
   PubMed Web of Science ®Google Scholar
• Cornish J, Kalivas P. Cocaine sensitization and craving: differing roles for dopamine and glutamate in the nucleus accumbens. J Act Dis 2001; 20: 43–54
   Google Scholar
• Baker D, McFarland K, Lake R, et al. Neuroadaptions in cystine – glutamate exchange underlie cocaine relapse. Nat Neurosci 2003; 6: 743–749
   PubMed Web of Science ®Google Scholar
• Dackis C. New treatments for cocaine abuse. Drug Discov Today Ther Strategies 2005; 2: 79–86
   Google Scholar
• Keys A, Mark G, Emre N, Meshul C. Reduced glutamate immunolabeling in the nucleus accumbens following extended withdrawal from self-administered cocaine. Synapse 1998; 30: 393–401
   PubMed Web of Science ®Google Scholar
• Murillo-Rodriguez E, Haro R, Palomero-Rivero M, Millan-Aldaco D, Drucker-Colin R. Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats. Behav Brain Res 2007; 176: 353–357
   PubMed Web of Science ®Google Scholar
• Madras B K, Xie Z, Lin Z, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 2006; 319: 561–569
   PubMed Web of Science ®Google Scholar
• Willie J, Renthal W, Chemelli R, et al. Modafinil more effectively induces wakefulness in norexin-null mice than wild-type littermates. Neuroscience 2005; 130: 983–995
   PubMed Web of Science ®Google Scholar
• Scammell T, Estabrooke I, McCarthy M, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J. Neurosci 2000; 20: 8620–8628
   PubMed Web of Science ®Google Scholar
• Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: preclinical, clinical, and post-marketing surveillance—a review of abuse liability issues. Ann Clin Psychiatry 2004; 16: 101–109
   PubMedGoogle Scholar
• Saletu B, Frey R, Krupka M, Anderer P, Grunberger J, Barbanoj M. Differential effects of a new central adrenergic agonist- modafinil and d-amphetamine on sleep and early morning behaviour in young healthy volunteers. Int J Clin Pharmacol Res 1989; 9: 183–185
   PubMedGoogle Scholar
• Robertson P, Hellriegel E. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003; 42: 123–137
   PubMed Web of Science ®Google Scholar
• Ballas C, Kim D, Baldassano C, Hoeh N. Modafinil: past, present and future. Exp Opin Neurother 2002; 2: 449–457
   PubMedGoogle Scholar
• de la Mora M, Aguilar-Garcia A, Ramon-Frias T, et al. Effects of the vigilance promoting drug modafinil on the synthesis of GABA and glutamate on slices of rat hypothalamus. Neurosci Lett 1999; 259: 181–185
   PubMed Web of Science ®Google Scholar
• Ferraro L, Antonelli T, Tanganelli S, et al. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial proptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology 1999; 20: 346–356
   PubMed Web of Science ®Google Scholar
• Ferraro L, Antonelli T, O'Connor W, Tanganelli S, Rambert F, Fuxe K. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport 1996; 82883–82887
   Web of Science ®Google Scholar
• Tanganelli S, Perez de la Mora M, Ferraro L, Mendez-Franco J, Beani L, Rambert F. Modafinil and cortical gamma-aminobutyric acid outflow: modulation by 5-HT neurotoxins. Eur J Pharmacol 1995; 273: 63–71
   PubMed Web of Science ®Google Scholar
• Dackis C, Lynch K, Yu E, et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003; 70: 29–37
   PubMed Web of Science ®Google Scholar
• Stoops W, Lile J, Fillmore M, Glaser P, Rush C. Reinforcing effects of modafinil: influence of dose and behavioural demands following drug administration. Psychopharmacology 2005; 182: 186–193
   PubMed Web of Science ®Google Scholar
• Turner D, Robbins T, Clark L, Aron A, Dowson J, Sahakian B. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology 2003; 165: 260–269
   PubMed Web of Science ®Google Scholar
• Jasinski D, Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 2000; 23: 149–156
   PubMed Web of Science ®Google Scholar
• Jasinski D. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000; 14: 53–60
   PubMed Web of Science ®Google Scholar
• Malcolm R, Brook S, Moak D, DeVane L, Czepowicz V. Clinical applications of modafinil in stimulant abusers: low abuse potential. Am J Addict 2002; 11: 247–249
   PubMed Web of Science ®Google Scholar
• Comacho A, Stein M. Modafinil for social phobia and amphetamine dependence [letter]. Am J Psychiatry 2002; 159: 1947–1948
   Web of Science ®Google Scholar
• McGregor C, White J, Srisurapanont M, Mitchell A, Wickes W. Investigation of potential pharmacotherapies for acute amphetamine withdrawal: open-label pilot studies of mirtazapine and modafinil. Paper presented at the Australian Professional Society on Alcohol and Other Drugs (APSAD), FremantleAustralia, 2004
   Google Scholar
• Malcolm R, Swayngim K, Donovan J, et al. Modafinil and cocaine interactions. Am J Drug Alcohol Abuse 2006; 32: 577–587
   PubMed Web of Science ®Google Scholar
• Dackis C, Kampman K, Lynch K, Pettinati H, O'Brien C. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005; 30: 205–211
   PubMed Web of Science ®Google Scholar